Erasca (ERAS) Share-based Compensation (2020 - 2026)
Erasca (ERAS) posted Share-based Compensation of $8.5 million for Q1 2026, up 45.29% on a QoQ basis from $5.8 million in Q4 2025, and up 26.02% year-over-year from $6.7 million in Q1 2025.
Erasca (ERAS) Share-based Compensation (2020 - 2026) Analysis & Trends
Erasca's Share-based Compensation history runs 7 years deep, the most recent figure standing at $8.5 million for Q1 2026.
- Quarterly Share-based Compensation rose 26.02% year-over-year to $8.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.6 million (down 0.72% YoY) and the FY2025 annual result came in at $24.9 million, down 30.64% from the prior year.
- Share-based Compensation was $8.5 million for Q1 2026 at Erasca, up from $5.8 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $8.5 million in Q1 2026 and bottomed at -$2.6 million in Q4 2022.
- A 5-year average of $5.8 million and a median of $6.3 million in 2024 frame the typical range for Share-based Compensation.
- Peak annual rise in Share-based Compensation reached 458.74% in 2022, while the deepest fall reached 190.01% in 2022.
- Erasca's Share-based Compensation stood at -$2.6 million in 2022, then jumped by 336.45% to $6.1 million in 2023, then gained by 2.8% to $6.3 million in 2024, then retreated by 7.69% to $5.8 million in 2025, then jumped by 45.29% to $8.5 million in 2026.
- Business Quant data shows ERAS's Share-based Compensation at $8.5 million in Q1 2026, $5.8 million in Q4 2025, and $6.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Erasca | 5.89 Bn | 5.89 Bn | - | 8.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.46 Mn |
| Mar 31, 2026 | 8.46 Mn |
| Dec 31, 2025 | 5.82 Mn |
| Dec 31, 2025 | 5.82 Mn |
| Sep 30, 2025 | 5.97 Mn |
| Sep 30, 2025 | 5.97 Mn |
| Jun 30, 2025 | 6.40 Mn |
| Jun 30, 2025 | 6.40 Mn |
| Mar 31, 2025 | 6.71 Mn |
| Mar 31, 2025 | 6.71 Mn |
| Dec 31, 2024 | 6.31 Mn |
| Dec 31, 2024 | 6.31 Mn |
| Sep 30, 2024 | 6.64 Mn |
| Sep 30, 2024 | 6.64 Mn |
| Jun 30, 2024 | 7.18 Mn |
| Jun 30, 2024 | 7.18 Mn |
| Mar 31, 2024 | 6.85 Mn |
| Mar 31, 2024 | 6.85 Mn |
| Dec 31, 2023 | 6.14 Mn |
| Dec 31, 2023 | 6.14 Mn |